Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark`s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella�2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. According to IQVIA sales data for the 12-month period ending January 2026, the Savella� Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million. Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. Glenmark`s Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi [NDA 212832]. Glenmark will begin distribution in March 2026.Powered by Capital Market - Live News

Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. Glenmark`s Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation has been determined by the FDA to be bioequivalent and therapeutically equivalent1 to the reference listed drug (RLD), FloVent�2 HFA Inhalation Aerosol, 44 mcg of GlaxoSmithKline Intellectual Property Ltd. England (NDA - 021433). Glenmark has been granted a Competitive Generic Therapy (CGT) designation for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation and is the �first approved applicant as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Glenmark is eligible for 180 days of CGT exclusivity upon commercialization. Glenmark`s Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026. The approval further strengthens Glenmark`s respiratory portfolio in the U.S. and underscores its commitment to expanding access to quality inhalation therapies. According to IQVIA sales data for the 12-month period ending January 2026, the FloVent� HFA Inhalation Aerosol, 44 mcg market3 achieved annual sales of approximately $520.1 million. Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials. Glenmark`s Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. [NDA 018892], with the 15 mM P/5 mL (3 mM P/mL) and 150 mM P/50 mL (3 mM P/mL) presentations expected to have the same therapeutic effect as that of the listed drug product upon which the FDA relied as the basis of safety and effectiveness. Glenmark will begin distribution in April 2026.Powered by Capital Market - Live News

Net profit of Glenmark Pharmaceuticals rose 15.88% to Rs 403.21 crore in the quarter ended December 2025 as against Rs 347.96 crore during the previous quarter ended December 2024. Sales rose 17.75% to Rs 3888.00 crore in the quarter ended December 2025 as against Rs 3301.90 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3888.003301.90 18 OPM %22.3718.18 - PBDT872.79579.06 51 PBT718.34456.33 57 NP403.21347.96 16 Powered by Capital Market - Live News